Molecular Mechanisms of Coronary Microvascular–Myocardial Communication During Cardiovascular Stress

Abstract

Coronary microvascular–myocardial communication is critical in adapting cardiac function to physiological and pathological stress. Recent advances have elucidated molecular pathways mediating this communication, especially under cardiovascular stress. This review synthesizes current knowledge on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic modalities, and therapeutic approaches, with a focus on molecular mechanisms and recent guideline recommendations. The evidence underscores the importance of microvascular integrity and endothelial signaling in maintaining myocardial homeostasis, highlighting implications for diagnosis and management in clinical practice.

Introduction

Cardiovascular stress precipitates a complex interplay between the coronary microvasculature and myocardial tissue. This communication is orchestrated through intricate molecular signals, ensuring adequate myocardial perfusion and contractile adaptation. Disruption of these pathways can lead to myocardial ischemia, dysfunction, and adverse cardiovascular outcomes, even in the absence of obstructive epicardial coronary disease. A deep understanding of these mechanisms is vital for clinicians, particularly given the rising recognition of microvascular dysfunction as a contributor to cardiovascular morbidity and mortality.

Epidemiology / Disease Burden

Coronary microvascular dysfunction (CMD) is increasingly recognized across diverse cardiac pathologies, affecting an estimated 20–30% of patients presenting with angina and non-obstructive coronary arteries. CMD prevalence is particularly high in women, individuals with diabetes, hypertension, and those with heart failure with preserved ejection fraction (HFpEF). The disease burden is substantial, as CMD is associated with a heightened risk of major adverse cardiovascular events, impaired quality of life, and recurrent hospitalizations. The underdiagnosis and undertreatment of microvascular dysfunction continue to pose significant challenges in contemporary cardiology.

Pathophysiology

Coronary microvascular–myocardial communication involves a bidirectional exchange of molecular signals. The endothelium of coronary microvessels synthesizes and releases nitric oxide (NO), prostacyclin, and endothelium-derived hyperpolarizing factors (EDHFs), which regulate vascular tone and myocardial oxygen delivery. During stress, shear stress and metabolic byproducts (adenosine, lactate, hydrogen ions) activate purinergic and G-protein coupled receptors on endothelial cells, stimulating the phosphoinositide 3-kinase (PI3K)/Akt pathway and increasing NO bioavailability.
Simultaneously, the myocardium releases paracrine factors (e.g., neuregulin-1, endothelin-1, reactive oxygen species) that modulate microvascular tone and permeability. Recent studies have highlighted the role of exosomes and microRNAs in intercellular communication, influencing angiogenesis, fibrosis, and inflammatory responses. Disruption of these mechanisms—via oxidative stress, inflammation, or metabolic derangements—impairs vasodilation and myocardial perfusion, predisposing to ischemia and contractile dysfunction.

Risk Factors

Risk factors for impaired coronary microvascular–myocardial communication include traditional cardiovascular risk factors (hypertension, diabetes mellitus, dyslipidemia, smoking) and emerging contributors such as chronic inflammation, autoimmune disease, and genetic predisposition. Estrogen deficiency post-menopause and metabolic syndrome also promote endothelial dysfunction. Notably, microvascular dysfunction is prevalent in patients with HFpEF and Takotsubo cardiomyopathy, highlighting the relevance of microvascular signaling in non-atherosclerotic cardiac syndromes.

Clinical Features

Patients with coronary microvascular dysfunction often present with exertional angina, dyspnea, or unexplained fatigue, mimicking classic obstructive coronary syndromes. However, non-obstructive findings on coronary angiography are typical. Microvascular angina may be associated with transient ECG changes and elevated biomarkers of myocardial strain, but lacks definitive anatomical stenosis. Recognition requires a high index of suspicion, particularly in women, diabetics, and those with persistent symptoms despite normal epicardial coronaries.

Diagnosis

Diagnosis of coronary microvascular dysfunction relies on a combination of non-invasive and invasive modalities. Non-invasive approaches include stress cardiac MRI, positron emission tomography (PET) to assess myocardial blood flow reserve, and transthoracic Doppler echocardiography of coronary flow reserve. Invasive techniques such as coronary flow reserve (CFR) measurement, index of microcirculatory resistance (IMR), and acetylcholine/provocative testing during coronary angiography provide direct assessment of microvascular function. Emerging biomarkers (e.g., circulating endothelial microparticles, specific microRNAs) show promise for non-invasive risk stratification.

Treatment & Management

Management focuses on optimizing cardiovascular risk factors and improving endothelial function. Pharmacological therapy includes statins, ACE inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and calcium channel blockers. Nitrates may provide symptomatic relief, though efficacy is variable. Novel agents targeting endothelial dysfunction such as ranolazine and ivabradine are under investigation. Lifestyle modifications, glycemic control, and exercise-based cardiac rehabilitation are critical adjuncts. In refractory cases, neuromodulation and enhanced external counterpulsation have been explored.

Recent Advances / Emerging Therapies

Recent research has focused on the molecular restoration of microvascular–myocardial signaling. Therapies targeting endothelial nitric oxide synthase (eNOS) coupling, antioxidant pathways (e.g., NADPH oxidase inhibitors), and mitochondrial function are being evaluated. MicroRNA-based therapeutics and exosome modulation represent cutting-edge strategies for enhancing microvascular repair and myocardial adaptation. Early-phase clinical trials of endothelin receptor antagonists and soluble guanylate cyclase stimulators have demonstrated potential benefits in select patient populations.

Guideline Recommendations

Current guidelines (ESC, AHA/ACC) emphasize the diagnostic evaluation of persistent angina with non-obstructive coronary arteries, recommending functional assessment of microvascular function in appropriate patients. Risk factor modification remains the cornerstone of management. Pharmacologic therapy should be individualized, and consideration of investigational agents may be warranted in refractory cases within specialized centers. Multidisciplinary care is advocated to address the complex interplay of comorbidities and optimize outcomes.

Conclusion

Coronary microvascular–myocardial communication is pivotal for myocardial adaptation to stress. Disruption of molecular signaling within the microvasculature contributes to ischemia, dysfunction, and adverse outcomes, underscoring the need for heightened clinical awareness and targeted interventions. Continued advances in molecular diagnostics and emerging therapeutics hold promise for improved patient stratification and personalized management in the era of precision cardiovascular medicine.